Wednesday, July 8, 2026

Drug profile · INN

ergocalciferol

ergocalciferol (ERGOCALCIFEROL) is a vitamin d receptor agonist. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 20
Pipeline programs 33
News articles 0
Drug details — ergocalciferol
US status
approved
Class
Route
ORAL
Patents
20
Programs
33
Data quality
0.84

Quick answer

ergocalciferol (ERGOCALCIFEROL) is a vitamin d receptor agonist. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN ergocalciferol
Brand ERGOCALCIFEROL
Mechanism Vitamin D receptor agonist
Target Vitamin D3 receptor
Route ORAL
Formulation CAPSULE

Mechanism of action

Vitamin D receptor agonist

Primary target: Vitamin D3 receptor

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. Cholecalciferol (Vitamin D/Vigantol oil) Phase 3 · United Therapeutics Europe · Respiratory Tract Infections
  2. UVEDOSE 100 000 UI, solution buvable en ampoule Phase 3 · Novo Nordisk A/S · Thyroidectomy is a common operation. Transient postoperative
  3. Vitamin D3 Phase 3 · Hospital Authority · Lupus Erythematosus, Systemic
  4. vitamin D Phase 3 · Takeda · COVID-19
  5. Vitamin D Phase 2 · United Therapeutics Europe · Breast Cancer
  6. Vitamin D3 Phase 2 · United Therapeutics Europe · Parkinson Disease
  7. CRC2024_01 Phase 1 · Théa Pharma Ireland · Patients with low Vitamin D plasma level
  8. Calcium 500 mg and Vitamin D3 800 IU Phase 1 · Takeda · Calcium Deficiency

Related & competitor drugs

  1. calcitriol Vitamin D receptor agonist
  2. doxercalciferol Vitamin D receptor agonist
  3. paricalcitol Vitamin D receptor agonist
  4. calcifediol Vitamin D receptor agonist
  5. calcipotriene Vitamin D receptor agonist
  6. calcipotriol + betamethasone dipropionate Vitamin D receptor agonist

Related patents

  1. US 12358976

    Methods for increasing serum concentration of phosphorous and/or 1,25-hydroxy vitamin d

    Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 12214021

    Study on lactoferrin regulation of bone formation by means of vitamin D receptor

    Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 12202822

    Addition salt of S1P1 receptor agonist and crystal form thereof, and pharmaceutical composition

    Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 12018255

    Compositions and methods for treating disorders of genomic imprinting

    Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 11952419

    Reagents and methods for treating cancer and autoimmune disease

    Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 11903952

    Vitamin D as an immune modulator to prevent immune-related complication from COVID-19 infection

    Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 11833254

    Discoidal nano universal platform for efficient delivery of PNAs

    Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 11512078

    Addition salt of S1P1 receptor agonist and crystal form thereof, and pharmaceutical composition

    Expires Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. US 11497197

    Methods for enhancing poultry growth and performance

    Expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  10. US 11479617

    Chelator-functionalized glycosaminoglycans

    Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  11. US 11390613

    Azole analogues and methods of use thereof

    Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  12. US 11364309

    Neuronal enhancers

    Expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  13. US 11103523

    Self-assembled brush block copolymer-nanoparticles for drug delivery

    Expires Mon Aug 26 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  14. US 11008378

    Compositions and methods for immunomodulation in an organism

    Expires Mon May 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  15. US 10814006

    Fluorescent prodrugs

    Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  16. US 10464993

    Compositions and methods for immunomodulation in an organism

    Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  17. US 10344040

    Pyridone and aza-pyridone compounds and methods of use

    Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  18. US 10280158

    Immune adjustment compound, use thereof and pharmaceutical composition comprising same

    Expires Mon May 02 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  19. US 10258635

    Formulations and compositions of vitamin D analogs for treating and preventing cancer and other diseases

    Expires Mon Apr 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  20. US 10053469

    Pyridone and aza-pyridone compounds and methods of use

    Expires Mon Aug 16 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is ergocalciferol?

ergocalciferol (ERGOCALCIFEROL) is a vitamin d receptor agonist. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for ergocalciferol?

ERGOCALCIFEROL is a marketed brand name for ergocalciferol. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of ergocalciferol?

ergocalciferol has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.